Editas Medicine (EDIT) Accumulated Expenses (2015 - 2025)
Editas Medicine (EDIT) posted quarterly Accumulated Expenses of $32.6 million for Q4 2025, down 28.89% year-over-year from $45.9 million in Q4 2024, and down 31.38% quarter-over-quarter from $47.5 million in Q3 2025.
Editas Medicine (EDIT) Accumulated Expenses (2015 - 2025) Analysis & Trends
Editas Medicine (EDIT) has reported Accumulated Expenses for 11 consecutive years, with $32.6 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Accumulated Expenses fell 28.89% year-over-year to $32.6 million; the TTM figure through Dec 2025 stood at $32.6 million (down 28.89% YoY), while the FY2025 annual figure was $32.6 million, down 28.89% from the prior year.
- Accumulated Expenses declined to $32.6 million in Q4 2025 per EDIT's latest filing, from $47.5 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $48.1 million in Q2 2025 and bottomed at $14.6 million in Q3 2021.
- Historically, Accumulated Expenses has averaged $29.4 million across 5 years, with a median of $29.5 million in 2023.
- Annual changes were most pronounced in 2023 — Accumulated Expenses soared 99.91% — and 2025, when it fell 28.89%.
- Editas Medicine's Accumulated Expenses stood at $20.2 million in 2021, then jumped by 54.99% to $31.3 million in 2022, then grew by 10.44% to $34.6 million in 2023, then surged by 32.68% to $45.9 million in 2024, then declined by 28.89% to $32.6 million in 2025.
- Business Quant data shows EDIT's Accumulated Expenses at $32.6 million in Q4 2025, $47.5 million in Q3 2025, and $48.1 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Editas Medicine | 263.01 Mn | 116.36 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 32.61 Mn |
| Sep 30, 2025 | 47.52 Mn |
| Jun 30, 2025 | 48.07 Mn |
| Mar 31, 2025 | 47.49 Mn |
| Dec 31, 2024 | 45.86 Mn |
| Sep 30, 2024 | 28.79 Mn |
| Jun 30, 2024 | 27.67 Mn |
| Mar 31, 2024 | 31.48 Mn |
| Dec 31, 2023 | 34.56 Mn |
| Sep 30, 2023 | 30.28 Mn |
| Jun 30, 2023 | 27.90 Mn |
| Mar 31, 2023 | 31.56 Mn |
| Dec 31, 2022 | 31.30 Mn |
| Sep 30, 2022 | 19.26 Mn |
| Jun 30, 2022 | 20.11 Mn |
| Mar 31, 2022 | 15.79 Mn |
| Dec 31, 2021 | 20.19 Mn |
| Sep 30, 2021 | 14.58 Mn |
| Jun 30, 2021 | 18.63 Mn |
| Mar 31, 2021 | 15.13 Mn |